MedPath

epoetin alfa

Generic Name
epoetin alfa
Clinical Trials
Related News

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Phase 3
Completed
Conditions
Anemia
Neoplasms
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
51
Registration Number
NCT00210587

A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Phase 2
Completed
Conditions
Chronic Kidney Disease
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-05-23
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
267
Registration Number
NCT00212875

Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Phase 2
Completed
Conditions
Anemia
Kidney Diseases
First Posted Date
2005-09-21
Last Posted Date
2011-05-23
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
67
Registration Number
NCT00210743

Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR)

Phase 4
Terminated
Conditions
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1432
Registration Number
NCT00211120

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2
Terminated
Conditions
Aged
Hemoglobins
Anemia
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
12
Registration Number
NCT00210795

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Phase 2
Withdrawn
Conditions
Anemia
Rheumatoid Arthritis
First Posted Date
2005-07-22
Last Posted Date
2016-09-20
Lead Sponsor
Ortho Biotech Products, L.P.
Registration Number
NCT00123149

Idiopathic Anemia of Aging (IAA)

Phase 2
Terminated
Conditions
Anemia
Aging
First Posted Date
2005-02-24
Last Posted Date
2008-08-29
Lead Sponsor
National Institute on Aging (NIA)
Registration Number
NCT00104169
Locations
🇺🇸

Harbor Hospital, Baltimore, Maryland, United States

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Phase 3
Completed
Conditions
Anemia
First Posted Date
2004-09-21
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1460
Registration Number
NCT00091910

A Study of Intravenous or Subcutaneous Methoxy Polyethylene Glycol-Epoetin Beta (RO0503821, Mircera) in Chronic Kidney Disease Patients With Renal Anemia

First Posted Date
2004-09-06
Last Posted Date
2012-02-14
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1228
Registration Number
NCT00090753

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Phase 3
Terminated
Conditions
Anemia
First Posted Date
2004-05-27
Last Posted Date
2011-04-27
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Registration Number
NCT00083486
Locations
🇺🇸

Southern Illinois Hematology, Centralia, Illinois, United States

🇺🇸

Spalding Oncology Services, Griffin, Georgia, United States

🇺🇸

NorthEast Urology Research, Concord, North Carolina, United States

and more 9 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy